MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEELAND
Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OZ Pharma Health is granted exclusive rights to market and sell Emtrix® in Australia and New Zeeland.
”The agreement is part of our international commercialization of Emtrix®, which now will be marketed in another large market. We currently have secured distributors for Emtrix® in over 20 markets,” comments Moberg Derma's CEO, Peter Wolpert.
About Emtrix® and nail diseases Emtrix® is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix® was initiated in the first markets in September 2010. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma Telephone: +46 8 522 307 00 Mobile: +46 735 71 35 E-mail: peter.wolpert@mobergderma.se
Magnus Persson, IR Mobile: +46 73-355 26 01 E-mail: magnus.persson@mobergderma.se
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 8 June, 08:00 am.
About Moberg Derma Moberg Derma AB (publ.), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers approved and launched products to projects in the preclinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se
Tags: